AAM
XLRN

Aberdeen Asset Management’s Acceleron Pharma XLRN Stock Holding History

Aberdeen Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-31,364
Closed -$800K – 766
2016
Q4 		$800K Buy
+31,364
New +$994K ﹤0.01% 660

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Aberdeen Asset Management's XLRN Position: Q1 2017 in Review

Aberdeen Asset Management sold out of Acceleron Pharma (XLRN) in Q1 2017, closing a stake of 31,364 shares — an estimated $800K sold.

Aberdeen Asset Management first reported a position in XLRN in Q4 2016 and held it in 1 quarter. The position peaked at $800K in Q4 2016. 136 funds tracked by Wall St. Rank hold XLRN as of Q1 2017.

  • Aberdeen Asset Management reported no remaining Acceleron Pharma position as of Q1 2017 after selling out during the quarter.
  • Aberdeen Asset Management sold 31,364 Acceleron Pharma shares in Q1 2017, an estimated $800K.
  • Aberdeen Asset Management first reported a position in Acceleron Pharma in Q4 2016 and held it in 1 quarter.
  • Aberdeen Asset Management's Acceleron Pharma position peaked at $800K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2017.

Based on Aberdeen Asset Management's 13F filing for Q1 2017, filed 10 May 2017.